Difference between revisions of "Dermatofibrosarcoma protuberans"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m (→NCCN) |
||
Line 14: | Line 14: | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
*[https://www.nccn.org/professionals/physician_gls/pdf/dfsp.pdf NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)] | *[https://www.nccn.org/professionals/physician_gls/pdf/dfsp.pdf NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)] | ||
+ | ===Older=== | ||
+ | *'''2014:''' Bichakjian et al. [https://doi.org/10.6004/jnccn.2014.0081 Dermatofibrosarcoma protuberans, version 1.2014] [https://pubmed.ncbi.nlm.nih.gov/24925197/ PubMed] | ||
+ | |||
=All lines of therapy= | =All lines of therapy= | ||
==Imatinib monotherapy {{#subobject:d700c4|Regimen=1}}== | ==Imatinib monotherapy {{#subobject:d700c4|Regimen=1}}== |
Revision as of 20:25, 25 May 2023
Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
2 variants on this page
|
Guidelines
NCCN
Older
- 2014: Bichakjian et al. Dermatofibrosarcoma protuberans, version 1.2014 PubMed
All lines of therapy
Imatinib monotherapy
Regimen variant #1, 400 mg/day
Study | Dates of enrollment | Evidence |
---|---|---|
Rutkowski et al. 2010 (SWOG S0345) | 2005-2006 | Phase 2, <20 pts |
Regimen variant #2, 800 mg/day
Study | Dates of enrollment | Evidence |
---|---|---|
Rutkowski et al. 2010 (EORTC 62027) | 2004-2007 | Phase 2, <20 pts (RT) |
Targeted therapy
- Imatinib (Gleevec) 400 mg PO twice per day
Continued indefinitely, unless complete (R0) surgical resection became possible
References
- EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00085475
- SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00084630